Company and Industry Summary Company: 罗新药业 (Luo Xin Pharmaceutical) Key Points - 罗新药业 is undergoing a transformation from a textile pharmaceutical company to an innovative pharmaceutical company, which has led to the divestiture of several subsidiaries over the past two years [1] - The company has not met its performance expectations, resulting in specific financial losses [1] - There has been a significant asset impairment loss related to the company's attempt to sell its subsidiary 乐康吃药 (Le Kang Pharmaceutical) [1] - In November 2024, the company is strategically optimizing its asset allocation by continuing to sell 乐康之钥 (Le Kang Zhi Yao), but has faced challenges in finding buyers, with the sale price decreasing after multiple attempts [1]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].

证券代码：002793 证券简称：罗欣药业 公告编号：2025-054 罗欣药业集团股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 三、业绩变动原因说明 1.公司核心创新药产品替戈拉生片的商业化进程进一步深化。商业团队在市 场拓展与准入方面取得积极进展，推动该产品在目标市场的终端覆盖持续扩大， 销量实现同比显著提升，成为业绩增长的重要动力。 2.本报告期内，公司持续优化营运资金管理，通过组织应收款项的专项清收 工作，有效改善公司经营性现金流的同时减少了坏账损失。 一、本期业绩预计情况 （二）业绩预告情况：扭亏为盈 | 项 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：1,500 | 万元-2,000 | 万元 | 亏损：8,871 | 万元 | | 扣除非经常性损益后的净利润 | 盈利：200 | 万元-300 | 万元 ...

Group 1 - The announcement details the progress of a share transfer agreement involving major shareholders of Luoxin Pharmaceutical Group Co., Ltd, specifically Chengdu De Yi Xin Hua Equity Investment Partnership and Karamay De Yi Heng Jia Equity Investment Partnership [1][2] - Chengdu De Yi Xin Hua plans to transfer 18,589,668 unrestricted circulating shares, while Karamay De Yi Heng Jia intends to transfer 35,789,757 unrestricted circulating shares to Shanghai Zhong Jue Private Fund Management Co., Ltd, resulting in a total transfer of 54,379,425 shares, which represents 5% of the company's total share capital [3][5] - A supplementary agreement has been signed, stipulating that the transferee, Zhong Jue Fund, commits not to transfer the acquired shares for 18 months following the completion of the share transfer [5][6] Group 2 - The agreement ensures compliance with relevant laws and regulations, confirming that the transfer does not harm the interests of the company or its shareholders, particularly minority shareholders [6] - The completion of the share transfer is subject to regulatory approval and may face uncertainties, which investors are advised to consider [6]

罗欣药业集团股份有限公司 简式权益变动报告书 上市公司：罗欣药业集团股份有限公司 上市地点：深圳证券交易所 股票简称：罗欣药业 股票代码：002793 信息披露义务人一：成都得怡欣华股权投资合伙企业（有限合伙） 通讯地址：成都市温江区光华大道三段 1588 号珠江国际中心写字楼 3502、3503 室 信息披露义务人二：克拉玛依市得怡恒佳股权投资有限合伙企业 通讯地址：新疆克拉玛依市克拉玛依区宝石路 278 号科研生产办公楼 A 座 519- 21-22 号 信息披露义务人三：克拉玛依市得怡欣华股权投资有限合伙企业 通讯地址：新疆克拉玛依市克拉玛依区宝石路 278 号科研生产办公楼 A 座 519- 21-23 号 信息披露义务人四：克拉玛依得怡健康产业投资有限合伙企业 通讯地址：新疆克拉玛依市南新路 75 号 信息披露义务人五：克拉玛依得盛健康产业投资有限合伙企业 通讯地址：新疆克拉玛依市克拉玛依区宝石路 278 号科研生产办公室 A 座 519- 21-24 号 股份变动性质：持股减少 签署日期：2025 年 7 月 9 日 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-053 罗欣药业集团股份有限公司 关于合计持股 5%以上股东协议转让公司部分股份进展 暨签署补充协议的公告 公司合计持股 5%以上股东成都得怡欣华股权投资合伙企业（有限合伙）、克 拉玛依市得怡恒佳股权投资有限合伙企业保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、本次协议转让的基本情况 2024 年 11 月 19 日，成都得怡欣华股权投资合伙企业（有限合伙）（以下简 称"得怡成都"）的管理人得怡投资管理（北京）有限公司（代表"得怡成都"）、 克拉玛依市得怡恒佳股权投资有限合伙企业（以下简称"得怡恒佳"）与上海中 珏私募基金管理有限公司（代表"中珏中钜增利一号私募证券投资基金"）（以下 简称"中珏基金"）签署了《股份转让协议》，得怡成都拟通过协议转让的方式向 中珏基金转让其持有的罗欣药业集团股份有限公司（以下简称"公司""本公司"） 无限售流通股 18,589,668 股；得怡恒佳拟通过协议转让的方式向中珏基金转让其 持有的本公司无限售流通 ...

Group 1 - The board of directors held its 25th meeting, which was legally convened and attended by all five directors [1][2] - The board approved the proposal to appoint Mr. Zuo Min as an independent director, pending approval from the shareholders' meeting [2][3] - The board agreed to adjust the special committee members, with Mr. Zuo Min set to join the Strategic Committee and Compensation and Assessment Committee after his appointment [3][4] Group 2 - The board proposed to amend the company's articles of association to reduce the number of board members from six to five [4][5] - The board scheduled the third extraordinary general meeting of shareholders for July 16, 2025, to discuss the proposed changes [5]

Group 1 - The company is named Luoxin Pharmaceuticals Group Co., Ltd and was established in accordance with the Company Law of the People's Republic of China [1] - The company was approved by the China Securities Regulatory Commission to issue 25 million shares of ordinary stock to the public on March 16, 2016, and was listed on the Shenzhen Stock Exchange on April 15, 2016 [1][3] - The registered capital of the company is RMB 1,087,588,486, with a total of 1,087,588,486 shares issued, all of which are ordinary shares [3][9] Group 2 - The company aims to maximize the interests of the company and its shareholders as its operational principle [4] - The business scope includes the production and wholesale of medical devices, pharmaceutical production, and related technical services [5] Group 3 - The company’s shares are issued in the form of stocks, with each share having a par value of RMB 1 [15] - The company’s shares are subject to equal rights for all shareholders, and the issuance of shares must adhere to principles of openness, fairness, and justice [15][16] Group 4 - The company has a total of 75 million ordinary shares at its establishment, with the total share capital fully subscribed by the founders [6][9] - The company’s founding shareholders include various individuals and entities, with specific contributions detailed [6][7][8]

罗欣药业集团股份有限公司 独立董事候选人声明与承诺 声明人左敏作为罗欣药业集团股份有限公司第五届董事会独立董事候选人，已充 分了解并同意由提名人罗欣药业集团股份有限公司董事会提名为罗欣药业集团股份 有限公司（以下简称"该公司"）第五届董事会独立董事候选人。现公开声明和保证， 本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立 性的要求，具体声明并承诺如下事项： 一、本人已经通过罗欣药业集团股份有限公司第五届董事会提名委员会或者独立 董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职情 形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任公司 董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务 规则规定的独立董事任职资格和条件。 ☑ 是 □ ...

罗欣药业集团股份有限公司 独立董事提名人声明与承诺 提名人罗欣药业集团股份有限公司（以下简称"罗欣药业"或"公司"）董 事会现就提名左敏先生为公司第五届董事会独立董事候选人发表公开声明。被提 名人已书面同意作为公司第五届董事会独立董事候选人。本次提名是在充分了解 被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良 记录等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规 章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性 的要求，具体声明并承诺如下事项： 一、被提名人已经通过公司第五届董事会提名委员会或者独立董事专门会议 资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 ☑ 是 □ 否 如否，请详细说明： 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明： 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 ☑ 是 □ 否 如否，请详细说明： 四、被提名人符合公司章程规定的独立董事任职条件。 ...